香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 自願性公告－ 拓益®新增適應症和君適達®納入國家醫保目錄 本公告由上海君實生物醫藥科技股份有限公司（「本公司」）自願作出。請亦參見本 公司於2025年12月7日刊發的海外監管公告。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司產品特瑞普利單抗注射液 （商品名：拓益®，產品代號：JS001）2項新增適應症、昂戈瑞西單抗注射液（商 品名：君適達®，產品代號：JS002）成功納入《國家基本醫療保險、生育保險和工 傷保險藥品目錄（2025年）》（「國家醫保目錄」）乙類範圍。新版國家醫保目錄將於 2026年1月1日起正式實施。 截至本公告日期，本公司4款商業化產品拓益®、阿達木單抗注射液（商品名：君 邁康®，產品代號：UBP1 ...

Core Viewpoint - Wanbangde demonstrates strong resilience in a challenging pharmaceutical manufacturing environment, achieving a revenue of 579 million yuan and a net profit of 13.46 million yuan in the first half of 2025 [1] Revenue Composition - The "Professional Equipment Manufacturing and Services" segment surpassed "Pharmaceutical Manufacturing" for the first time, contributing 41.63% to the company's revenue, primarily due to the impact of national procurement policies [1] R&D Investment - The company increased its R&D investment to 31.14 million yuan, a year-on-year growth of 13.48%, focusing on the development of traditional Chinese medicine, chemical drugs, and raw materials [2] Transition to Innovative Drugs - Wanbangde is shifting from generic drugs to innovative drugs, with seven ongoing innovative drug projects, including "WP103" and "WP107," which have received clinical trial approval in the U.S. [3][4] Addressing Disease Trends - The company is developing new drugs targeting obesity and Alzheimer's disease, with significant progress in clinical trials and patent approvals for innovative combinations [4] Strengthening R&D Capabilities - Wanbangde is enhancing its R&D capabilities by attracting high-end talent and building a competitive technology development platform, while also exploring AI applications in drug development [5] International Expansion - The company is actively pursuing international markets, with its South African operations generating 172 million yuan in revenue, a 1.45% increase, and a net profit of 6.21 million yuan, up 884.25% [6] Global Market Recognition - Wanbangde's medical device products have received multiple international certifications, including FDA and CE approvals, and the company has significant production capacity for various medical devices [6] Strategic Development - The company plans to continue its focus on the pharmaceutical manufacturing and medical device sectors, integrating its operations with the "Belt and Road" initiative to enhance long-term growth [7]